Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro

Journal of Neurochemistry
Kenjiro Ono, Masahito Yamada

Abstract

The aggregation of alpha-synuclein (alphaS) in the brain has been implicated as a critical step in the development of Lewy body diseases (LBD) and multiple system atrophy (MSA). Various antioxidants not only inhibit the formation of beta-amyloid fibrils (fAbeta), but also destabilize preformed fAb in vitro. Using fluorescence spectroscopy with thioflavin S and electron microscopy, here we examined the effects of the antioxidants nordihydroguaiaretic acid, curcumin, rosmarinic acid, ferulic acid, wine-related polyphenols [tannic acid, myricetin, kaempferol (+)-catechin and (-)-epicatechin], docosahexaenoic acid, eicosapentaenoic acid, rifampicin and tetracycline on the formation of alphaS fibrils (falphaS) and on preformed falphaS. All molecules, except for docosahexaenoic acid and eicosapentaenoic acid, dose-dependently inhibited the formation of falphaS. Moreover, these molecules dose-dependently destabilized preformed falphaS. The overall activity of the molecules examined was in the order of: tannic acid=nordihydroguaiaretic acid=curcumin=rosmarinic acid=myricetin>kaempferol=ferulic acid>(+)-catechin=(-)-epicatechin>rifampicin=tetracycline. These compounds with anti-fibrillogenic as well as antioxidant activities could be ke...Continue Reading

References

Oct 1, 1992·Free Radical Biology & Medicine·E Graf
Apr 1, 1986·The Journal of Investigative Dermatology·Y MiyachiY Niwa
Oct 14, 1994·Biochemical and Biophysical Research Communications·T TomiyamaN Endo
May 23, 1994·FEBS Letters·R JakesM Goedert
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K UédaT Saitoh
Aug 1, 1996·Journal of Neuropathology and Experimental Neurology·M C IrizarryB T Hyman
Mar 1, 1996·Journal of Neuropathology and Experimental Neurology·L S Forno
Sep 24, 1996·Biochemical and Biophysical Research Communications·C SotoB Frangione
Jan 1, 1997·The Journal of Pharmacy and Pharmacology· Sreejayan, M N Rao
Jan 1, 1996·Journal of Cellular Biochemistry. Supplement·G J KelloffC C Sigman
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·A LomakinG B Benedek
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Aug 1, 1997·Journal of Pharmaceutical and Biomedical Analysis·Y J WangJ K Lin
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Oct 3, 1999·Methods in Enzymology·H Naiki, F Gejyo
Oct 8, 1999·Journal of the American College of Nutrition·K N PrasadB Kumar
Nov 5, 1999·Journal of Molecular Biology·P E Wright, H J Dyson
Mar 18, 2000·The Journal of Nutrition·G J KelloffC C Sigman
Apr 4, 2000·Nature·M B Feany, W W Bender
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·L C SerpellR A Crowther
Aug 31, 2000·Neurobiology of Disease·Y ZhangT M Dawson
Jan 22, 2001·The Journal of Biological Chemistry·V N UverskyA L Fink
Feb 13, 2001·FEBS Letters·G ForloniM Salmona
Mar 7, 2001·Biological Psychiatry·H ZengM G Zagorski
Apr 5, 2001·Journal of Molecular Biology·D EliezerG Browne
May 12, 2001·Mechanisms of Ageing and Development·D A Butterfield, J Kanski
May 31, 2001·Journal of Molecular Graphics & Modelling·A K DunkerZ Obradovic

❮ Previous
Next ❯

Citations

Jan 15, 2008·Acta Neuropathologica·Neeraj PandeyJames E Galvin
Jul 17, 2008·Journal of Molecular Modeling·Ugo CosentinoMario Salmona
Oct 12, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Dawn BéraudKathleen A Maguire-Zeiss
Feb 5, 2009·Neuromolecular Medicine·Albert Y SunGrace Y Sun
Feb 17, 2009·Journal of Molecular Neuroscience : MN·Pei RenJun-Xia Xie
Mar 23, 2010·Molecular Neurobiology·Albert Y SunGrace Y Sun
Jun 29, 2007·Expert Reviews in Molecular Medicine·Jean-Christophe Rochet
May 31, 2008·Journal of the American Chemical Society·Jillian MadineDavid A Middleton
Aug 23, 2008·Antioxidants & Redox Signaling·A Raquel EstevesSandra M Cardoso
Aug 23, 2011·Neurochemical Research·Seema Jagota, Jayakumar Rajadas
Sep 22, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Elvira Valera, Eliezer Masliah
Oct 4, 2011·Trends in Neurosciences·Kiren UbhiEliezer Masliah
Jul 28, 2009·Biophysical Chemistry·Steven S-S WangWen-Hsuan Lee
May 2, 2008·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Shih-Hao HuangBeen-Huang Chiang
Jan 11, 2013·BioFactors·Adriana MonroySilvestre Alavez
Nov 12, 2013·British Journal of Pharmacology·A GrubmanJ R Liddell
Dec 15, 2006·Neurobiology of Aging·Esther Dalfó, Isidre Ferrer
Jul 15, 2015·Neurochemistry International·M D PandareeshM M Srinivas Bharath
May 27, 2015·CNS Neuroscience & Therapeutics·Edy KorneliusChien-Ning Huang
Jun 1, 2012·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Nelson FerreiraMaria Rosário Almeida
Jul 11, 2012·The International Journal of Neuroscience·Safiya KhanYasir Hasan Siddique

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.